Page 12 - Program Updates News Today

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision

Other in English on Türkiye about Coordination and Earthquake; published on 19 Apr 2023 by UNHCR

-  NDA submission for etripamil in patients with PSVT currently on track for 3Q23 -  Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on... | May 11, 2023

11.05.2023 - Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy analyses ...

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Presented initial preclinical data from ETX-123, Eliems lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability ... | May 11, 2023

Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed...

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives ... | May 10, 2023

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson... | May 10, 2023

08.05.2023 - Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) - Prelude Therapeutics Incorporated (Nasdaq: ...